Overview

AZD6765 for Treatment Resistant Depression

Status:
Completed

Trial end date:
2007-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca